fda bpc-157 safety warning In a major policy shift, the U.S. Food and Drug Administration is reconsidering restrictions on several controversial peptides, including trending compounds like and Melanotan II. The move comes as demand for “ BPC-157: Experimental Peptide Creates Risk
Description
Increased angiogenesis in people with accompanying cancer can lead to accelerated formation of the tumor's vascular network, which may speed up disease progression, including through the formation of metastases

According to the inspection report, one case involved a patient with severe gastrointestinal issues and a 3-night hospital stay after taking a compounded semaglutide injection

Restoration of p53 function leads to tumour regression in vivo

Handa K, Inukai K, Onuma H, Kudo A, Nakagawa F, Tsugawa K,
